Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity

Chaolin Huang, Yuanhong Chen, Hang Liu, Jing Yang, Xuejing Song, Junping Zhao, Na He, Chengji Zhou, Yongping Wang, Changjiang Huang, Qiaoxiang Dong

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes.

Original languageEnglish (US)
Pages (from-to)115254-115269
Number of pages16
JournalOncotarget
Volume8
Issue number70
DOIs
StatePublished - Jan 1 2017

Fingerprint

Celecoxib
Wnt Signaling Pathway
Neoplastic Stem Cells
Dinoprostone
Breast Neoplasms
Anti-Inflammatory Agents
Pharmaceutical Preparations
Epithelial-Mesenchymal Transition
Adjuvant Chemotherapy
Colorectal Neoplasms
Neoplasms
Carcinogenesis

Keywords

  • Celecoxib
  • CSCs
  • EMT
  • PGE
  • Wnt pathway

ASJC Scopus subject areas

  • Oncology

Cite this

Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. / Huang, Chaolin; Chen, Yuanhong; Liu, Hang; Yang, Jing; Song, Xuejing; Zhao, Junping; He, Na; Zhou, Chengji; Wang, Yongping; Huang, Changjiang; Dong, Qiaoxiang.

In: Oncotarget, Vol. 8, No. 70, 01.01.2017, p. 115254-115269.

Research output: Contribution to journalArticle

Huang, C, Chen, Y, Liu, H, Yang, J, Song, X, Zhao, J, He, N, Zhou, C, Wang, Y, Huang, C & Dong, Q 2017, 'Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity', Oncotarget, vol. 8, no. 70, pp. 115254-115269. https://doi.org/10.18632/oncotarget.23250
Huang, Chaolin ; Chen, Yuanhong ; Liu, Hang ; Yang, Jing ; Song, Xuejing ; Zhao, Junping ; He, Na ; Zhou, Chengji ; Wang, Yongping ; Huang, Changjiang ; Dong, Qiaoxiang. / Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. In: Oncotarget. 2017 ; Vol. 8, No. 70. pp. 115254-115269.
@article{2f972c668e8b4b1992f9c34d52d44d0c,
title = "Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity",
abstract = "Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes.",
keywords = "Celecoxib, CSCs, EMT, PGE, Wnt pathway",
author = "Chaolin Huang and Yuanhong Chen and Hang Liu and Jing Yang and Xuejing Song and Junping Zhao and Na He and Chengji Zhou and Yongping Wang and Changjiang Huang and Qiaoxiang Dong",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23250",
language = "English (US)",
volume = "8",
pages = "115254--115269",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "70",

}

TY - JOUR

T1 - Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity

AU - Huang, Chaolin

AU - Chen, Yuanhong

AU - Liu, Hang

AU - Yang, Jing

AU - Song, Xuejing

AU - Zhao, Junping

AU - He, Na

AU - Zhou, Chengji

AU - Wang, Yongping

AU - Huang, Changjiang

AU - Dong, Qiaoxiang

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes.

AB - Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes.

KW - Celecoxib

KW - CSCs

KW - EMT

KW - PGE

KW - Wnt pathway

UR - http://www.scopus.com/inward/record.url?scp=85039749553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039749553&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23250

DO - 10.18632/oncotarget.23250

M3 - Article

AN - SCOPUS:85039749553

VL - 8

SP - 115254

EP - 115269

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 70

ER -